Article

Methemoglobin aggregation is modulated by the anti-sickling drug voxelotor

2024-06-17

Abstract excerpt

<h4>ABSTRACT</h4> Sickle cell disease is caused by a mutation in the beta subunit of hemoglobin (HbSS) that drives Hb fiber formation when the protein is in the deoxygenated (tense, T) state. The drug voxelotor was recently approved to treat sickle cell disease by preventing HbSS fiber formation. Voxelotor acts as an allosteric inhibitor of polymerization by maintaining the HbSS protein in the relaxed (R) conform...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1f8fbf00-dfc9-5914-9405-b90e6af43d42
DOI: 10.1101/2024.06.16.599216

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Methemoglobin aggregation is modulated by the anti-sickling drug voxelotorDOI 10.1101/2024.06.16.599216Read

Osivelotor for the treatment of sickle cell diseaseSemantic proximity Read

VZHE-039, a novel antisickling agent that prevents erythrocyte sickling under both hypoxic and anoxic conditionsSemantic proximity Read

Assessing the Clinical Outcomes of Voxelotor Treatment in Patients with Sickle Cell DiseaseSemantic proximity Read

Voxelotor Treatment Interferes With Quantitative and Qualitative Hemoglobin Variant Analysis in Multiple Sickle Cell Disease Genotypes.Semantic proximity Read

Emerging drug targets for sickle cell disease: shedding light on new knowledge and advances at the molecular levelSemantic proximity Read

In Silico Post-screening of Anti-polymerization Agents to Treat Sickle Cell DiseaseSemantic proximity Read

Rapid withdrawal of Voxelotor can precipitate sickle cell disease related crisisSemantic proximity Read

Targeting sickle cell disease root-cause pathophysiology with small moleculesSemantic proximity Read

Voxelotor in adolescents and adults with sickle cell disease (HOPE): long-term follow-up results of an international, randomised, double-blind, placebo-controlled, phase 3 trial.Semantic proximity Read

Hemoglobin C is prone to oxidative denaturation, resulting in red blood cell membrane damage in HbSC diseaseSemantic proximity Read

Differential sensitivity to hypoxia enables shape‐based classification of sickle cell disease and trait blood samples at point of careSemantic proximity Read

Phenotypic screening of the ReFrame Drug Repurposing Library to discover new drugs for treating sickle cell diseaseSemantic proximity Read